📊 RPRX Key Takeaways
Is Royalty Pharma plc (RPRX) a Good Investment?
Royalty Pharma demonstrates exceptional operating profitability with 65.6% margins and outstanding free cash flow generation of 2.5B, but faces concerning near-term headwinds including flat net income growth despite 5.1% revenue expansion and 6.8% EPS decline from shareholder dilution. The company's modest 7.9% ROE combined with elevated leverage (0.92x debt/equity) raises questions about capital efficiency and sustainable growth in a mature pharmaceutical royalty portfolio business.
Why Buy Royalty Pharma plc Stock? RPRX Key Strengths
- Exceptional operating margin of 65.6% demonstrating superior pricing power and operational leverage in royalty monetization
- Outstanding free cash flow generation of 2.5B with 104.7% FCF margin indicating exceptional cash conversion efficiency
- Strong balance sheet liquidity with 2.40x current ratio and fortress-like interest coverage of 35.3x providing significant financial flexibility
RPRX Stock Risks: Royalty Pharma plc Investment Risks
- Earnings quality deterioration: flat net income YoY despite 5.1% revenue growth suggests margin compression or rising operational expenses
- Shareholder value erosion with 6.8% EPS decline and 14 Form 4 insider filings in 90 days indicating capital structure stress and potential dilution concerns
- Elevated leverage with 9.0B debt relative to 9.7B equity limits strategic flexibility in slow-growth royalty business model with limited organic growth catalysts
Key Metrics to Watch
- Net income growth trajectory - critical to confirm if earnings stabilize or continue decelerating relative to revenue growth
- Organic royalty portfolio expansion rate - fundamental to assessing long-term value creation capability
- Net debt reduction and debt-to-EBITDA ratio progression - essential for evaluating capital structure sustainability and deleveraging pace
Royalty Pharma plc (RPRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 104.7% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 2.40x current ratio provides a solid financial cushion.
RPRX Profit Margin, ROE & Profitability Analysis
RPRX vs Healthcare Sector: How Royalty Pharma plc Compares
How Royalty Pharma plc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Royalty Pharma plc Stock Overvalued? RPRX Valuation Analysis 2026
Based on fundamental analysis, Royalty Pharma plc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Royalty Pharma plc Balance Sheet: RPRX Debt, Cash & Liquidity
RPRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Royalty Pharma plc's revenue has shown modest growth of 4% over the 5-year period. The most recent EPS of $2.53 reflects profitable operations.
RPRX Revenue Growth, EPS Growth & YoY Performance
RPRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $564.7M | $288.2M | $0.67 |
| Q2 2025 | $537.3M | $30.2M | $0.07 |
| Q1 2025 | $568.0M | $4.8M | $0.01 |
| Q3 2024 | $536.3M | $72.1M | $0.16 |
| Q2 2024 | $537.3M | $102.0M | $0.23 |
| Q1 2024 | $568.0M | $4.8M | $0.01 |
| Q3 2023 | $536.3M | $72.1M | $0.16 |
| Q2 2023 | $536.0M | $227.6M | $0.50 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Royalty Pharma plc Dividends, Buybacks & Capital Allocation
RPRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Royalty Pharma plc (CIK: 0001802768)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RPRX
What is the AI rating for RPRX?
Royalty Pharma plc (RPRX) has an AI rating of HOLD with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RPRX's key strengths?
Claude: Exceptional operating margin of 65.6% demonstrating superior pricing power and operational leverage in royalty monetization. Outstanding free cash flow generation of 2.5B with 104.7% FCF margin indicating exceptional cash conversion efficiency.
What are the risks of investing in RPRX?
Claude: Earnings quality deterioration: flat net income YoY despite 5.1% revenue growth suggests margin compression or rising operational expenses. Shareholder value erosion with 6.8% EPS decline and 14 Form 4 insider filings in 90 days indicating capital structure stress and potential dilution concerns.
What is RPRX's revenue and growth?
Royalty Pharma plc reported revenue of $2.4B.
Does RPRX pay dividends?
Royalty Pharma plc pays dividends, with $378.3M distributed to shareholders in the trailing twelve months.
Where can I find RPRX SEC filings?
Official SEC filings for Royalty Pharma plc (CIK: 0001802768) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RPRX's EPS?
Royalty Pharma plc has a diluted EPS of $1.78.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RPRX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Royalty Pharma plc has a HOLD rating with 75% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RPRX stock overvalued or undervalued?
Valuation metrics for RPRX: ROE of 7.9% (sector avg: 15%), net margin of 32.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RPRX stock in 2026?
Our dual AI analysis gives Royalty Pharma plc a combined HOLD rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is RPRX's free cash flow?
Royalty Pharma plc's operating cash flow is $2.5B, with capital expenditures of N/A. FCF margin is 104.7%.
How does RPRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 32.4% (avg: 12%), ROE 7.9% (avg: 15%), current ratio 2.40 (avg: 2).